Nagatsu T, Sawada M
Department of Pharmacology, School of Medicine, Fujita Health University, Toyoake, Aichi, Japan.
J Neural Transm Suppl. 2006(71):53-65. doi: 10.1007/978-3-211-33328-0_7.
Monoamine oxidases A and B (MAO A and MAO B) are the major enzymes that catalyze the oxidative deamination of monoamine neurotaransmitters such as dopamine (DA), noradrenaline, and serotonin in the central and peripheral nervous systems. MAO B is mainly localized in glial cells. MAO B also oxidizes the xenobiotic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to a parkinsonism-producing neurotoxin, 1-methyl-4-phenyl-pyridinium (MPP+). MAO B may be closely related to the pathogenesis of Parkinson's disease (PD), in which neuromelanin-containing DA neurons in the substantia nigra projecting to the striatum in the brain selectively degenerate. MAO B degrades the neurotransmitter DA that is deficient in the nigro-striatal region in PD, and forms H2O2 and toxic aldehyde metabolites of DA. H2O2 produces highly toxic reactive oxygen species (ROS) by Fenton reaction that is catalyzed by iron and neuromelanin. MAO B inhibitors such as L-(-)-deprenyl (selegiline) and rasagiline are effective for the treatment of PD. Concerning the mechanism of the clinical efficacy of MAO B inhibitors in PD, the inhibition of DA degradation (a symptomatic effect) and also the prevention of the formation of neurotoxic DA metabolites, i.e., ROS and dopamine derived aldehydes have been speculated. As another mechanism of clinical efficacy, MAO B inhibitors such as selegiline are speculated to have neuroprotective effects to prevent progress of PD. The possible mechanism of neuroprotection of MAO B inhibitors may be related not only to MAO B inhibition but also to induction and activation of multiple factors for anti-oxidative stress and anti-apoptosis: i.e., catalase, superoxide dismutase 1 and 2, thioredoxin, Bcl-2, the cellular poly(ADP-ribosyl)ation, and binding to glyceraldehydes-3-phosphate dehydrogenase (GAPDH). Furthermore, it should be noted that selegiline increases production of neurotrophins such as nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and glial cell line-derived neurotrphic factor (GDNF), possibly from glial cells, to protect neurons from inflammatory process.
单胺氧化酶A和B(MAO A和MAO B)是催化中枢和外周神经系统中多巴胺(DA)、去甲肾上腺素和5-羟色胺等单胺类神经递质氧化脱氨的主要酶。MAO B主要定位于神经胶质细胞。MAO B还将外源性物质1-甲基-4-苯基-1,2,3,6-四氢吡啶(MPTP)氧化为一种导致帕金森症的神经毒素1-甲基-4-苯基吡啶鎓(MPP+)。MAO B可能与帕金森病(PD)的发病机制密切相关,帕金森病中脑黑质中投射到纹状体的含神经黑色素的DA神经元选择性退化。MAO B降解PD黑质纹状体区域中缺乏的神经递质DA,并形成H2O2和DA的有毒醛类代谢产物。H2O2通过铁和神经黑色素催化的芬顿反应产生剧毒的活性氧(ROS)。MAO B抑制剂如L-(-)-司来吉兰(左旋丙炔苯丙胺)和雷沙吉兰对PD治疗有效。关于MAO B抑制剂对PD临床疗效的机制,推测有对DA降解的抑制作用(一种对症作用)以及对神经毒性DA代谢产物即ROS和多巴胺衍生醛类形成的预防作用。作为临床疗效的另一种机制,推测司来吉兰等MAO B抑制剂具有神经保护作用以防止PD进展。MAO B抑制剂神经保护的可能机制可能不仅与MAO B抑制有关,还与多种抗氧化应激和抗凋亡因子的诱导和激活有关,即过氧化氢酶、超氧化物歧化酶1和2、硫氧还蛋白、Bcl-2、细胞多聚(ADP-核糖基)化以及与甘油醛-3-磷酸脱氢酶(GAPDH)的结合。此外,应该注意到司来吉兰增加神经营养因子如神经生长因子(NGF)、脑源性神经营养因子(BDNF)和胶质细胞系源性神经营养因子(GDNF)的产生,可能来自神经胶质细胞,以保护神经元免受炎症过程的影响。